Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Dr. Lal PathLabs Limited ( (IN:LALPATHLAB) ) has provided an update.
Dr. Lal PathLabs Limited has submitted to the Indian stock exchanges the official transcript of its Q4 and full-year FY26 earnings conference call, held on April 30, 2026, in compliance with SEBI’s disclosure regulations. The call, led by CEO Shankha Banerjee and Group CFO and CEO–International Business Ved Prakash Goel, featured participation from multiple institutional investors and analysts, underscoring sustained market interest in the company’s financial performance and strategic outlook.
More about Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited is an Indian diagnostic services company operating a network of pathology laboratories and collection centers that provide a wide range of clinical testing services. The company serves patients, hospitals, and healthcare providers, with its shares listed on the National Stock Exchange of India and BSE under the symbol LALPATHLAB and scrip code 539524.
Average Trading Volume: 45,043
Technical Sentiment Signal: Strong Buy
Current Market Cap: 263.6B INR
Learn more about LALPATHLAB stock on TipRanks’ Stock Analysis page.